All In Biotech

Drug Trial Radar · NCT03836716

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial

Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

120

Actual

Start

Sep 19, 2019

Primary completion

Jul 2, 2021

Study completion Jul 2, 2021

Sponsor

Lead sponsor
ZevraDenmarkIndustry
Sponsor type
Industry
First posted
Feb 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ArimoclomolDrug

    2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
  2. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (1)Time frame: Week 76
  3. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Hematology (2)Time frame: Week 76
  4. Mean and Change From Baseline in Clinical Safety Laboratory Tests - ErythrocytesTime frame: Week 76
  5. Mean and Change From Baseline in Clinical Safety Laboratory Tests - HematocritTime frame: Week 76
  6. Mean and Change From Baseline in Clinical Safety Laboratory Tests - HemoglobinTime frame: Week 76
  7. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (1)Time frame: Week 76
  8. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (2)Time frame: Week 76
  9. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Clinical Chemistry (3)Time frame: Week 76
  10. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Albumin and ProteinTime frame: Week 76
  11. Mean and Change From Baseline in Clinical Safety Laboratory Tests - Cystatin CTime frame: Week 76
  12. Mean and Change From Baseline in Vital Signs - Blood PressureTime frame: Week 76
  13. Mean and Change From Baseline in Vital Signs - Pulse RateTime frame: Week 76
  14. Mean and Change From Baseline in Vital Signs - Respiratory RateTime frame: Week 76
  15. Mean and Change From Baseline in Vital Signs - TemperatureTime frame: Week 76
  16. Number of Participants With Potentially Clinically Significant Abnormalities in Clinical Safety Laboratory Tests and Vital Signs Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks
  17. Columbia-Suicide Severity Rating Scale (C-SSRS) Over the Open-label Treatment PeriodTime frame: From Day 1 in ORARIALS-02 to Early Termination, an average of approximately 28 weeks

Locations

23 sites in 11 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center

    Phoenix, Arizona

  • UC Irvine Health ALS and Neuromuscular Center

    Orange, California

  • University of Miami

    Miami, Florida

  • Hospital for Special Surgery

    New York, New York

  • Providence Brain & Spine Institute

    Portland, Oregon

  • University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center

    Philadelphia, Pennsylvania

  • University of Virginia Health System

    Charlottesville, Virginia

  • Catholic University Leuven

    Leuven, Belgium

  • London Health Sciences Centre

    London, Ontario, Canada

  • Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac

    Montpellier, France

  • Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422

    Paris, France

  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen

    Berlin, Germany

  • Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie

    Hanover, Germany

  • Universitaetsklinikum Ulm - Klinik fuer Neurologie

    Ulm, Germany

  • Instituti Clinica Scientifici Maugeri

    Milan, Italy

  • Azienda Ospedaliero Universitaria (AUO) di Torino - Citta'della Salute e della Scienza di Torino

    Torino, Italy

  • University Medical Center Utrecht

    Utrecht, Netherlands

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • Citi Clinic

    Warsaw, Poland

  • Hospital Universitario Vall d'Hebron ALS Unit. Consultas Externas; Office: 9-10-11

    Barcelona, Spain

  • Hospital Carlos III - Hospital Universitario La Paz, ALS Unit

    Madrid, Spain

  • Umeå University Hospital

    Umeå, Sweden

  • Leonard Wolfson Experimental Neurology Centre

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.